New Agents for Taxol-Resistant Breast Adenocarcinoma
Abstract
Taxol has proven to be a valuable addition to the chemotherapeutic regimens that can be offered to breast cancer patients; however, as with other drugs, evidence for resistance to Taxol has emerged. Among these resistance mechanisms is the P-gp 170 membrane-associated drug-efflux pump, for which the active agent, paclitaxel, is a substrate, and over-expression of the oncogene, HER-2/neu. Both of these resistance mechanisms are widely associated with breast cancer. Strategies to address Taxol-resistance include its combination with other chemotherapeutic agents and dose-intensification. However, in recent randomized clinical trials, the latter has proven to be largely ineffective, with little meaningful clinical benefit at the price of severe toxicities. Therefore, new agents and strategies are urgently needed to address Taxol-resistant breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2004
- Accession Number
- ADA432040
Entities
People
- Jim Klostergaard
Organizations
- The University of Texas MD Anderson Cancer Center